B. Stancil

发表

HIV prevention trial design in an era of effective pre-exposure prophylaxis

R. D. Meyer, D. Glidden, D. Dunn, 2017, HIV clinical trials.

Unexpected Finding of Delayed-Onset Seizures in HIV-Positive, Treatment-Experienced Subjects in the Phase Iib Evaluation of Fosdevirine (Gsk2248761)

J. Eron, E. Dejesus, D. Margolis, 2014, Antiviral therapy.

Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results

B. Ha, E. Dejesus, C. Small, 2013, BMC Infectious Diseases.

High sensitivity of HLA-B*5701 in Whites and Blacks in immunologically-confirmed cases of abacavir hypersensitivity (ABC HSR)

S. Mallal, M. Saag, E. Phillips, 2007 .

Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial.

J. Gallant, R. Grant, I. Frank, 2017, The lancet. HIV.

Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial.

J. Eron, Kimberly Smith, W. Spreen, 2015, The Lancet. Infectious diseases.

Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trial

R. Grant, I. Frank, M. Murray, 2018, HIV clinical trials.

Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utility

D. Burns, E. Lai, S. Hetherington, 2008, The Pharmacogenomics Journal.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients.

S. Mallal, M. Saag, E. Phillips, 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection.

R. Levine, D. Rockey, H. Makhlouf, 2010, Gastroenterology.

Long-Term Efficacy, Safety, and Durability of Cabotegravir and Rilpivirine as 2-Drug Oral Maintenance Therapy After 6 Years of Study

W. Spreen, J. Baril, E. Dejesus, 2022, Open forum infectious diseases.

96-Week Results of a Pilot Study of Abacavir/Lamivudine and Raltegravir in Antiretroviral-Naïve HIV-1–Infected Patients: The SHIELD Trial

B. Ha, T. Hawkins, E. Dejesus, 2011, HIV clinical trials.

Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection.

R. Levine, D. Rockey, H. Makhlouf, 2010, Gastroenterology.

96-Week Results of a Pilot Study of Abacavir/Lamivudine and Raltegravir in Antiretroviral-Naïve HIV-1–Infected Patients: The SHIELD Trial

T. Vanig, B. Stancil, Benjamin Young, 2011, HIV clinical trials.

Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial.

J. Gallant, R. Grant, I. Frank, 2017, The lancet. HIV.